Novartis will share late-breaking Phase 3 ianalumab results and CAR-T data at ACR Convergence 2025
Novartis announced plans to present data from 27 company- or investigator-sponsored abstracts across its Immunology portfolio and pipeline at the 2025 American College of Rheumatology (ACR) Convergence. Data… read more.

